Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MAIA Biotechnology, Inc. (MAIA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into MAIA’s clinical progress, financing transactions, and investor communications around its lead investigational therapy, ateganosine (THIO).
MAIA frequently uses Form 8-K to report material events such as private placement financings, the entry into Securities Purchase Agreements for common stock and warrants, and the intended use of proceeds to fund specific steps in its THIO-101 Phase 2 trial and broader working capital needs. These filings also incorporate press releases as exhibits, covering topics like insider open-market share purchases, initiation of the THIO-104 Phase 3 pivotal trial in advanced NSCLC, and updates on enrollment and poster presentations at conferences including SITC, AACR-NCI-EORTC, and ESMO.
Through its 8-K filings, MAIA additionally furnishes investor presentation materials and scientific posters that describe the design of its Phase 2 and Phase 3 studies, the telomere-targeting mechanism of ateganosine, and regulatory milestones such as U.S. FDA Fast Track designation for NSCLC and Orphan Drug Designations in other tumor types. These documents help investors understand how MAIA structures its clinical program, how it sequences ateganosine with checkpoint inhibitors, and how it communicates emerging data to the oncology community.
On Stock Titan, MAIA’s filings are updated in line with EDGAR, and AI-powered summaries can help explain the significance of individual reports, such as financing-related 8-Ks or other event-driven disclosures. Users can review these filings to track MAIA’s capital formation activities, clinical trial disclosures, and the formal record of press releases and presentations that shape the company’s regulatory and development narrative.
MAIA Biotechnology filed an 8-K to share that it issued a press release announcing positive efficacy data from its THIO-101 Phase 2 clinical trial in non-small cell lung cancer. This suggests the company is seeing encouraging signals from THIO-101 in a difficult-to-treat cancer setting, although detailed results are contained in the attached press release rather than this summary document.
The company also includes standard cautionary language that these are forward-looking statements and that actual outcomes may differ due to clinical, regulatory, manufacturing, market acceptance, and intellectual property risks. No financial figures or commercial timelines are discussed in this filing.
MAIA Biotechnology, Inc. filed a current report describing new clinical data communication activities. The company prepared a scientific poster showing efficacy data from its Phase 2 THIO-101 trial, which evaluates THIO given in sequence with the immune checkpoint inhibitor cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer who had already failed two or more standard-of-care treatments.
The poster was selected as an abstract titled “Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS” and was presented at the 2025 IASLC World Conference on Lung Cancer on September 7, 2025. MAIA plans to post the same poster on its website on September 8, 2025 and has filed it as Exhibit 99.1 to this report. The company notes that the poster includes forward-looking statements and cautions investors not to place undue reliance on them.
MAIA Biotechnology reported that the European Patent Office has decided to grant a patent that broadly covers a portfolio of ateganosine-based analogues directed to telomere-targeting anticancer therapy. The patent also covers methods of using ateganosine (THIO) either alone or prior to administration of checkpoint inhibitors (CPIs). The filing attaches a press release as Exhibit 99.1 which is incorporated by reference.
The filing contains the Companys standard forward-looking statements cautioning that future results are subject to risks and uncertainties, including the initiation, timing, cost, progress and results of preclinical and clinical studies, regulatory filings and approvals, manufacturing and commercialization, market acceptance, and intellectual property protection. No financial results or transaction terms are disclosed in this report.
MAIA Biotechnology, Inc. reported unaudited condensed consolidated results for the quarter ended June 30, 2025. The company held $10,144,522 in cash and reported total assets of $11,045,854 and total liabilities of $7,169,170, leaving stockholders' equity of $3,876,684. The company had 31,818,480 shares issued and outstanding at June 30, 2025 and 32,993,220 shares outstanding as of August 11, 2025.
Operating expenses for the quarter were $5.17 million (R&D $3.11M; G&A $2.06M). Net loss was $5.35 million in the quarter and $9.86 million for the six months, narrower than the prior-year six-month loss of $16.95M; basic and diluted loss per share was $0.34 for the six months. Net cash used in operating activities for six months was $8.34 million; net cash provided by financing activities was $8.87 million from ATM sales and multiple private placements.
The filing discloses substantial doubt about the company’s ability to continue as a going concern within one year, noting an accumulated deficit of $97,099,055 and that additional equity or debt financing will be required.